Annual variability in the seasonal cycles of chlorophyll, nutrients and zooplankton on the North-West European continental shelf

Seasonal cycles of salinity, nutrients, chlorophyll and zooplankton at 8 locations on the West-European shelf were analysed with respect to their timing and magnitude in the period 1980-1984. A late spring bloom with low chlorophyll values (2-4 mg.m-³) is observed in the Irish Sea, off the Scottish east coast and the Channel entrance. An early spring bloom and relatively high chlorophyll values (7-12 mg.m-³) are found in the southern Bight and the Skagerrak, whereas a late spring bloom with high chlorophyll concentrations (24 mg.m-³) is found along the Dutch and Belgian coast. In contrast to the other regions, the peak of the phytoplankton cycle in the German Bight (Helgoland) occurs in the summer period instead of the spring period. The peak in the yearly abundance of copepods shifts from May-June in the south to July-August in the north of the shelf. In the Irish Sea and the Channel entrance two seasonal copepods peaks are observed. The January nitrate values in Irish Sea, the southern Bight and the Skagerrak are about 20 % higher than those in the Atlantic input signal in the Channel entrance and east off Scotland. The January DIP values in these regions are comparable to those of the input signal, but the Irish Sea forms an exception here the level is increased by 10-20%. If compared with the Atlantic input signal the January values for nitrate and DIP at the Dutch and Belgium coast are about 10 and 4, and in the German Bight (Helgoland) 4 and 3 times higher, respectively. At most sites changes in the seasonal cycles of chorophyll coincide with changes in nutrient concentrations, wheras the maximum level of the seasonal signal is related to the nutrient levels

Transgenic Expression of P1A Induced Thymic Tumor: A Role for Onco-Fetal Antigens in Tumorigenesis

P1A is the first known tumor rejection antigen. It is expressed in embryonic stem cells and multiple tumors but is silent in adult tissues except for the testis and placenta. Therefore, P1A represents a prototype for onco-fetal antigens. To test the potential function of P1A in tumorigenesis, we used a transgenic mouse expressing P1A in lymphoid cells. We observed that immunodeficient host P1A transgenic mice developed thymic tumors after 7 months of age and had shorter survival rates compared to control groups. Most of the 7 examined tumors displayed B cell lineage markers. The P1A transgenic bone marrow cells had higher proliferation ability and more potential progenitors compared to control bone marrow cells. To our knowledge, our data provided the first example that onco-fetal antigen can promote tumorigenesis

C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.

PURPOSE: Tumor regression has been observed in some patients with metastatic renal cell carcinoma (RCC) after nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). Cellular and molecular characterization of antigens recognized by tumor-reactive T cells isolated from responding patients could potentially provide insight into the mechanisms of tumor regression. EXPERIMENTAL DESIGN: CD8+ CTL clones that recognized a novel RCC-associated minor histocompatibility (H) antigen presented by HLA-A*0201 were isolated from two patients with metastatic RCC who experienced tumor regression or stable disease following nonmyeloablative allogeneic HCT. These clones were used to screen a cDNA library and isolate the unique cDNA encoding the antigen. RESULTS: An alternative open reading frame in the C19orf48 gene located on chromosome 19q13 encodes the HLA-A*0201-restricted minor H antigen recognized by the RCC-reactive T cells. The differential T-cell recognition of donor- and recipient-derived target cells is attributable to a nonsynonymous single-nucleotide polymorphism within the nucleotide interval that encodes the antigenic peptide. Assays for gene expression and CTL recognition showed that the C19orf48-encoded peptide is widely expressed in renal tumors and solid tumors of other histologies. The antigenic peptide can be processed for CTL recognition via both TAP-dependent and TAP-independent pathways. CONCLUSIONS: Donor T-cell responses against the HLA-A*0201-restricted minor H antigen encoded by C19orf48 may contribute to RCC regression after MHC-matched allogeneic HCT